Literature DB >> 23375563

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.

Keith A Johnson1, Reisa A Sperling, Christopher M Gidicsin, Jeremy S Carmasin, Jacqueline E Maye, Ralph E Coleman, Eric M Reiman, Marwan N Sabbagh, Carl H Sadowsky, Adam S Fleisher, P Murali Doraiswamy, Alan P Carpenter, Christopher M Clark, Abhinay D Joshi, Ming Lu, Michel Grundman, Mark A Mintun, Michel J Pontecorvo, Daniel M Skovronsky.   

Abstract

OBJECTIVE: To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).
METHODS: Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.
RESULTS: Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.
CONCLUSIONS: : The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Amyvid; Florbetapir; Mesh; PET

Mesh:

Substances:

Year:  2013        PMID: 23375563      PMCID: PMC3800236          DOI: 10.1016/j.jalz.2012.10.007

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  41 in total

1.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

2.  PET imaging of amyloid deposition in patients with mild cognitive impairment.

Authors:  Anton Forsberg; Henry Engler; Ove Almkvist; Gunnar Blomquist; Göran Hagman; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Neurobiol Aging       Date:  2007-05-11       Impact factor: 4.673

3.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

4.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

5.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

6.  Amyloid deposition is associated with impaired default network function in older persons without dementia.

Authors:  Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson
Journal:  Neuron       Date:  2009-07-30       Impact factor: 17.173

7.  Amyloid imaging in mild cognitive impairment subtypes.

Authors:  David A Wolk; Julie C Price; Judy A Saxton; Beth E Snitz; Jeffrey A James; Oscar L Lopez; Howard J Aizenstein; Ann D Cohen; Lisa A Weissfeld; Chester A Mathis; William E Klunk; Steven T De-Kosky; Steven T DeKoskym
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

8.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11

9.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

10.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Authors:  Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  98 in total

1.  Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.

Authors:  P Payoux; J Delrieu; A Gallini; D Adel; A S Salabert; A Hitzel; C Cantet; M Tafani; D De Verbizier; J Darcourt; Ph Fernandez; J Monteil; I Carrié; T Voisin; S Gillette-Guyonnet; M Pontecorvo; B Vellas; S Andrieu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-08       Impact factor: 9.236

2.  Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

Authors:  Susan M Resnick; Murat Bilgel; Abhay Moghekar; Yang An; Qing Cai; Mei-Cheng Wang; Madhav Thambisetty; Jerry L Prince; Yun Zhou; Anja Soldan; Dean F Wong; Richard J O'Brien; Luigi Ferrucci; Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2015-04-04       Impact factor: 4.673

3.  Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.

Authors:  Saffire H Krance; Hugo Cogo-Moreira; Jennifer S Rabin; Sandra E Black; Walter Swardfager
Journal:  J Neurosci       Date:  2019-07-26       Impact factor: 6.167

4.  Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration.

Authors:  Corey T McMillan; David J Irwin; Ilya Nasrallah; Jeffrey S Phillips; Meredith Spindler; Katya Rascovsky; Kylie Ternes; Charles Jester; David A Wolk; Linda K Kwong; Virginia M-Y Lee; Edward B Lee; John Q Trojanowski; Murray Grossman
Journal:  Acta Neuropathol       Date:  2016-11-04       Impact factor: 17.088

5.  Correlation between two methods of florbetapir PET quantitative analysis.

Authors:  Christopher Breault; Jonathan Piper; Abhinay D Joshi; Sara D Pirozzi; Aaron S Nelson; Ming Lu; Michael J Pontecorvo; Mark A Mintun; Michael D Devous
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

6.  Mild to moderate Alzheimer dementia with insufficient neuropathological changes.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Deborah Blacker; Teresa Gómez-Isla; Rebecca A Betensky; John H Growdon; Keith A Johnson; Matthew P Frosch; Reisa A Sperling; Bradley T Hyman
Journal:  Ann Neurol       Date:  2014-04-08       Impact factor: 10.422

7.  Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Authors:  Ian Diner; Jeromy Dooyema; Marla Gearing; Lary C Walker; Nicholas T Seyfried
Journal:  Bioconjug Chem       Date:  2017-09-22       Impact factor: 4.774

8.  Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.

Authors:  A P Nayate; J G Dubroff; J E Schmitt; I Nasrallah; R Kishore; D Mankoff; D A Pryma
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

9.  Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings.

Authors:  Bliss Elizabeth O'Bryhim; Rajendra S Apte; Nathan Kung; Dean Coble; Gregory P Van Stavern
Journal:  JAMA Ophthalmol       Date:  2018-11-01       Impact factor: 7.389

10.  Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.

Authors:  Timothy S Chang; Edmond Teng; David Elashoff; Joshua D Grill
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.